Thrombosis associated with l‐asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia
Authors:
Open Access
- 18 November 2004
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 77 (4) , 331-335
Abstract
L‐Asparaginase is a chemotherapeutic agent commonly used in the treatment of both adult and pediatric acute lymphoblastic leukemia (ALL). A major complication is thrombosis, resulting from reduced synthesis of proteins such as antithrombin III. Hypofibrinogenemia, also a side effect, may be a marker of thrombosis and decreased protein synthesis. A retrospective chart review of identically treated patients revealed 9 thrombotic events among 93 patients (10%), 6 (7%) occurring during treatment cycles including l‐asparaginase. Twelve (13%) patients had fibrinogen levels P = 0.014). Therefore, a fibrinogen <50 mg/dL may serve as a marker for a hypercoagulable state in ALL patients receiving l‐asparaginase. Am. J. Hematol. 77:331–335, 2004.Keywords
This publication has 17 references indexed in Scilit:
- A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginaseCancer, 2003
- Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2002
- Thrombosis Related to the Use of L-Asparaginase in Adults with Acute Lymphoblastic Leukemia: a Need to Consider Coagulation Monitoring and Clotting Factor ReplacementLeukemia & Lymphoma, 1999
- Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemiaLeukemia, 1998
- Disseminated Intravascular Coagulation in Adult Acute Lymphoblastic Leukemia: Frequent Complications with Fibrinogen Levels Less than 100 mg/dlLeukemia & Lymphoma, 1996
- Minimal effects ofE. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: A randomized studyMedical and Pediatric Oncology, 1994
- Asparaginase RevisitedLeukemia & Lymphoma, 1993
- Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L‐asparaginase during induction therapy: A retrospective studyEuropean Journal of Haematology, 1992
- Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapyAmerican Journal of Hematology, 1989
- A syndrome of thrombosis and hemorrhage complicating l-asparaginase therapy for childhood acute lymphoblastic leukemiaThe Journal of Pediatrics, 1982